论文部分内容阅读
目的观察胸腔灌注吉西他滨治疗NSCLC致恶性胸腔积液的疗效。方法 80例NSCLC伴恶性胸腔积液患者随机分为2组,实验组予胸腔灌注吉西他滨1.0g～1.2g/次,对照组予胸腔灌注顺铂60mg～80mg/次,每周用药1次,连用3周。结果吉西他滨组、顺铂组治疗总有效率分别为85.7%和78.9%,差异无统计学意义。吉西他滨组生活质量改善率优于顺铂组(P<0.05),两组毒副反应相近。结论胸腔灌注吉西他滨治疗NSCLC致恶性胸腔积液有良好疗效,且毒副作用轻,生活质量改善明显。
Objective To observe the curative effect of thoracic perfusion of gemcitabine on NSCLC-induced malignant pleural effusion. Methods Eighty NSCLC patients with malignant pleural effusion were randomly divided into 2 groups. The experimental group was given intrathoracic injection of gemcitabine 1.0g ~ 1.2g / time, the control group was given intrapleural cisplatin 60mg ~ 80mg / time, once a week, 3 weeks. Results The total effective rates of gemcitabine group and cisplatin group were 85.7% and 78.9% respectively, with no significant difference. The quality of life improvement in gemcitabine group was better than that in cisplatin group (P <0.05). The side effects were similar in both groups. Conclusions Thoracic perfusion of gemcitabine has a good curative effect in the treatment of malignant pleural effusions with NSCLC. The toxicities and side effects are mild and the quality of life is improved obviously.